BCL9 and cancer: Given these factors, many efforts have been made for the development of bioactive peptides that block the β-catenin/Bcl9 interaction in cancer therapy, for instance, hsBCL9CT-24 [28], sulfono-γ-AA [29], and ECRV [30].